Phase III trial of brivanib in patients with hepatocellular carcinoma in China
Phase of Trial: Phase III
Latest Information Update: 25 Mar 2015
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors ZAI Lab
- 25 Mar 2015 Title is not official.
- 25 Mar 2015 New trial record
- 23 Mar 2015 Bristol-Myers Squibb and ZAI Lab have entered a licensing agreement under which ZAI Lab will develop brivanib alaninate in China, according to a media release.